Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049361 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049361: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT00049361 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049361, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation therapy with thalidomide and temozolomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining whole-brain radiation therapy with thalidomide and temozolomide in treating patients who have newly diagnosed brain metastases.
Interventions
- DRUG temozolomide
- RADIATION radiation therapy
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-01-01 |
| Est. Completion | 2004-12-07 |
| Phase | Phase 2 |
What the finished NCT00049361 record still lists
NCT00049361 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00049361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049361 about?
NCT00049361 is a clinical study titled "Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation ther...
What is the current status of trial NCT00049361?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-01-01. Estimated completion is 2004-12-07.
What interventions are being tested in trial NCT00049361?
The interventions under investigation include: temozolomide (DRUG), radiation therapy (RADIATION), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00049361?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI